ISIS Pharmaceuticals Inc. (NASDAQ:ISIS) recently added two new drugs, FGFR4Rx and STAT3Rx, to its development pipeline. FGFR4Rx is designed to treat obesity by increasing metabolism, mainly by increasing lipid and fat burning. FGFR4Rx blocks the production of fibroblast growth factor receptor 4, or FGFR4, in the liver and fat tissue.

According to Sanjay Bhanot, M.D., Ph.D., vice president, Metabolic Disorders and Head of Translational Medicine at Isis Pharmaceutical, preclinical studies of the product demonstrated reductions in body fat, reversal of existing obesity and improved insulin sensitivity, making it a promising drug with an exciting therapeutic profile.

STAT3Rx treats cancer by inhibiting the production of a gene critical for tumor cell growth and survival.  STAT3Rx in its preclinical studies demonstrated antitumor activity in animal models of human cancer with an attractive safety profile.  STAT3Rx would be evaluated in a variety of cancers where STAT3 is believed to play a key role such as liver cancers and multiple myeloma.

Isis engages in antisense technology, exploiting a drug discovery platform created to generate first-in-class drugs.

Genzyme Corp. (NASDAQ:GENZ) recently soared with news of a confidentiality pact with Sanofi Aventis (NYSE: SNV) that would allow Sanofi to conduct a due diligence as merger talks between the two companies await. The pact will allow Sanofi to access sensitive data related to profit margins, price lists, customer contracts, financial forecasts, among others.

The previous offer by Sanofi was rejected by the company on the basis of undervaluation. The recent offer includes pricing of $69.0 per share or $18.5 billion for all the outstanding shares of the company. Prior to this offer, the reports allude Sanofi’s confidence in a deal with Genzyme for an overall price of about $76 per share, including guaranteed value certificates which depend on future performance. The total consideration would include the cash component and a contingent value right or CVR. The CVR structure provides additional milestone payments to be made to the target company after it meets certain sales or regulatory targets in future. The CVR structure has been a contentious issue between the two companies. The pricing of the deal would emphasize the valuation of Genzyme’s multiple sclerosis drug Campath, known generically as alemtuzumab and to be branded as Lemtrada. The company predicts revenues of Lemtrada to hit $3.5 billion in 2017 and Sanofit forecasts a modest $700 million.

Genzyme focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune disease. It operates through four business segments including, Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology.

• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• See today’s top stock picks and market analysis
• Want more? Check out the message board buzz for these stocks
• See what newsletters are recommending these stock picks
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
• This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.

About BeaconEquity.com

BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

Beacon Equity Group Disclaimer

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.